Development and validation of a combined ultrasound-pathology model to predict axillary status after neoadjuvant systemic therapy in breast cancer

开发和验证一种结合超声和病理的模型,用于预测乳腺癌新辅助全身治疗后腋窝淋巴结状态

阅读:2

Abstract

Background: This study aimed to develop a combined ultrasound (US)-pathology model to predict the axillary status more accurately after NST in breast cancer. Methods: This retrospective study included breast cancer patients who received NST at the First Affiliated Hospital of Nanjing Medical University from 2015 to 2022. Clinical, US, and pathological data were collected. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of axillary pathological complete response (pCR). The model was developed using the predictors and validated. Results: A total of 657 patients were enrolled in this study. Two multivariate logistic analyses were performed before and after the operation. The results showed that the clinical lymph nodes, ER status, HER2 status, chemotherapy response of primary tumor, hilum structure of axillary lymph nodes (ALNs) after NST, blood flow of ALNs after NST, vascular invasion, pathological size, and Miller-Payne grade (all p < 0.05) were independent predictors of axillary pCR. The US-based and combined US-pathology models were developed based on preoperative and postoperative information. The two models had an area under the receiver operating characteristic curve (AUC) of 0.821 and 0.883, respectively, which was significantly higher than that of the fine-needle aspiration model (AUC: 0.735). Conclusion: In this study, based on the US-based model, a combined model incorporating the characteristics of ALNs under US and breast pathology was developed and validated to predict axillary pCR.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。